Discover inclusive, trauma-informed sexual health insights using science-based models and therapies. This comprehensive, science-based textbook is designed for upper-level college, graduate students, and professionals in psychology, psychotherapy, counseling, social work, and other related fields. Written from a gender-expansive, non-binary, and intersex-inclusive framework, the textbook integrates feminist research and intersectionality throughout its chapters, offering a positive and empowered approach to sexual health. It addresses a wide range of topics, including the Dual Control Model of sexual desire, developmental and aging sexual health, and non-monogamous relationships such as polyamory. Treatment strategies span Eye Movement Desensitization and Reprocessing Therapy (EMDR), Cognitive Behavioral Therapy (CBT), systemic approaches, medical interventions, and psychoeducation to address sexual health and treatment, with the potential impact of trauma as a central theme. CourseConnect: Know, use, and test your understanding of course content with CourseConnect--an interactive learning platform included with your print purchase. Key Features: Inclusive, pleasure-positive guide to sexual health, concerns, and treatment across diverse populations Builds competence in treating sexual issues using EMDR, CBT, systemic, and psychodynamic methods Includes client-ready handouts, case studies, anatomy diagrams, and tools for diverse learning needs Authored by leading experts with contributions from national and international specialists Instructor's Manual includes test banks, discussion questions, and chapter-based supplemental content Maximize Your Learning With CourseConnect--Included With Your Print Purchase! Enhance your textbook experience with CourseConnect, an interactive learning platform designed to help you engage more deeply, study smarter, and achieve success in your course. Master Complex Concepts--Interactive learning activities simplify concepts and improve comprehension and retention. Track Your Progress--Real-time analytics and self-assessments help you identify strengths and focus on areas for improvement. Study Anytime, Anywhere--Enjoy seamless access to your eBook and study tools whenever and wherever you need them.

Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp.

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring at an annual incidence rate of approximately 1.1 to 2.1 per 100,000 person-years globally. Approximately 40% of annual ALL cases occur in adults, yet estimated 5-year overall survival rates are about 40% to 50% in adults (and vary broadly by age) compared with 90% in children. Although the addition and/or intensification of asparaginase as a key treatment strategy for pediatric ALL is well recognized, further research is needed to clarify the benefit/risk ratio in adult patients with ALL. This review emphasizes the importance of efficient management of adverse events to increase asparaginase efficacy and explores novel strategies for optimizing asparaginase treatment, including new formulations of asparaginase, pharmacokinetic-based dosing, and pharmacogenetic profiling. Upcoming results of adult ALL trials should further clarify the role of asparaginase, building on the results of the large NOPHO 2008, CALGB 10403, GRAALL-2005, GMALL 07/2003, and UKALL14 trials.